Dendritic cell-based adjuvant immunotherapy has already shown a gain in CD8 T cells in peripheral blood in non-luminal BC, with an encouraging progression-free survival improvement suggesting benefits of systemic immunity [16]. The gene discussed is CD8A; the disease is breast cancer.